Canadian Vaccine Passes First Human Trial for Top Diarrhea Bug

Imagine a vaccine that could prevent millions of cases of food poisoning every year, especially while traveling. Canadian scientists just made that dream one giant step closer to reality.

University of Guelph researchers announced their vaccine against campylobacter jejuni successfully passed its first human trial. The bacteria causes more cases of severe diarrhea than salmonella or E. coli, yet most people have never heard of it.

"We've all had our bouts of food poisoning and diarrhea, especially when travelling," said Mario Monteiro, the chemistry professor who led the 20-year project. The bacteria lurks in raw or undercooked chicken and can cause fever, cramps, and diarrhea lasting several days.

Between 2022 and 2024, about 60 healthy adults received three doses of the vaccine at Cincinnati Children's Hospital Medical Centre. The trial showed the vaccine safely raised antibodies against the bacteria with minimal side effects like muscle soreness and fatigue.

Children in developing countries face the highest risk from this infection. Repeated bouts can actually stunt their growth, making a vaccine potentially life-changing for vulnerable populations worldwide.

The World Health Organization already recognized this vaccine as a preferred product. That's a remarkable achievement for something developed entirely in a university lab rather than by a major pharmaceutical company.

The Ripple Effect

Monteiro credits 30 to 40 graduate and undergraduate students who contributed to the vaccine over two decades. These students didn't just assist with research. They made fundamental discoveries about sugar-based vaccines that could change how we prevent bacterial diseases.

The vaccine uses a unique approach where Monteiro's lab identifies sugar antigens from bacteria and makes them trigger immune responses. This same technique has already led to three other human trials for campylobacter vaccines and one for C. difficile, another dangerous bacteria.

"With some things, you get immediate satisfaction. But science is not one of them," Monteiro said. He teaches his students that patience matters more than speed when making real breakthroughs.

Phase two trials come next, testing whether the vaccine actually prevents illness when people are exposed to live bacteria. Hundreds of volunteers will receive either the vaccine or a placebo before being intentionally infected to measure protection.

If phase two succeeds, the team hopes to create a multivalent version covering multiple strains of the bacteria at once. Phase three would eventually test the vaccine on hundreds of thousands of people worldwide.

The U.S. National Institutes of Health funded the trial, recognizing how this Canadian innovation could benefit travelers, military personnel, and vulnerable populations globally. Monteiro said government support makes all the difference in turning decades of lab work into real-world solutions.

After 20 years of steady progress, this vaccine proves that university labs can compete with industry giants when passion meets patience.